These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 32864046)

  • 21. The Role of Overweight and Obesity in the Cardiorenal Syndrome.
    Sowers JR; Whaley-Connell A; Hayden MR
    Cardiorenal Med; 2011; 1(1):5-12. PubMed ID: 22258461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levels of Proinflammatory Cytokines, Oxidative Stress, and Tissue Damage Markers in Patients with Acute Heart Failure with and without Cardiorenal Syndrome Type 1.
    Virzì GM; Breglia A; Brocca A; de Cal M; Bolin C; Vescovo G; Ronco C
    Cardiorenal Med; 2018; 8(4):321-331. PubMed ID: 30205401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiorenal syndrome.
    Ronco C; Haapio M; House AA; Anavekar N; Bellomo R
    J Am Coll Cardiol; 2008 Nov; 52(19):1527-39. PubMed ID: 19007588
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI).
    Cruz DN; Schmidt-Ott KM; Vescovo G; House AA; Kellum JA; Ronco C; McCullough PA
    Contrib Nephrol; 2013; 182():117-36. PubMed ID: 23689659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiorenal syndrome caused by heart failure with preserved ejection fraction.
    Lazzeri C; Valente S; Tarquini R; Gensini GF
    Int J Nephrol; 2011 Feb; 2011():634903. PubMed ID: 21331316
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics.
    Chung EYM; Trinh K; Li J; Hahn SH; Endre ZH; Rogers NM; Alexander SI
    Front Cardiovasc Med; 2022; 9():868658. PubMed ID: 35669475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apocynin Attenuates Cardiac Injury in Type 4 Cardiorenal Syndrome via Suppressing Cardiac Fibroblast Growth Factor-2 With Oxidative Stress Inhibition.
    Liu Y; Liu Y; Liu X; Chen J; Zhang K; Huang F; Wang JF; Tang W; Huang H
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26109504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: implications for cardiorenal syndrome.
    Liu S; Kompa AR; Kumfu S; Nishijima F; Kelly DJ; Krum H; Wang BH
    Int J Cardiol; 2013 Oct; 168(3):1866-80. PubMed ID: 23347614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens-From a Cardiologist's View.
    Mitsas AC; Elzawawi M; Mavrogeni S; Boekels M; Khan A; Eldawy M; Stamatakis I; Kouris D; Daboul B; Gunkel O; Bigalke B; van Gisteren L; Almaghrabi S; Noutsias M
    J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498617
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RAAS inhibition and cardiorenal syndrome.
    Onuigbo MA
    Curr Hypertens Rev; 2014; 10(2):107-11. PubMed ID: 25549841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity.
    Agrawal A; Naranjo M; Kanjanahattakij N; Rangaswami J; Gupta S
    Heart Fail Rev; 2019 Jul; 24(4):421-437. PubMed ID: 31127482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in pathogenesis and current therapeutic strategies for cardiorenal syndrome.
    Du Y; Li X; Liu B
    Life Sci; 2014 Mar; 99(1-2):1-6. PubMed ID: 24140889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiorenal syndrome at different stages of chronic kidney disease.
    Tsagalis G; Zerefos S; Zerefos N
    Int J Artif Organs; 2007 Jul; 30(7):564-76. PubMed ID: 17674332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative stress in the cardiorenal metabolic syndrome.
    Whaley-Connell A; Sowers JR
    Curr Hypertens Rep; 2012 Aug; 14(4):360-5. PubMed ID: 22581415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Target organ cross talk in cardiorenal syndrome: animal models.
    Bongartz LG; Braam B; Gaillard CA; Cramer MJ; Goldschmeding R; Verhaar MC; Doevendans PA; Joles JA
    Am J Physiol Renal Physiol; 2012 Nov; 303(9):F1253-63. PubMed ID: 22914779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiorenal syndrome: long road between kidney and heart.
    Junho CVC; Trentin-Sonoda M; Panico K; Dos Santos RSN; Abrahão MV; Vernier ICS; Fürstenau CR; Carneiro-Ramos MS
    Heart Fail Rev; 2022 Nov; 27(6):2137-2153. PubMed ID: 35133552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications.
    Matsushita K
    Curr Pharm Des; 2016; 22(30):4629-4637. PubMed ID: 27160756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer.
    Forte V; Pandey A; Abdelmessih R; Forte G; Whaley-Connell A; Sowers JR; McFarlane SI
    Cardiorenal Med; 2012 May; 2(2):143-162. PubMed ID: 22851963
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathogenesis and treatment of the cardiorenal syndrome: Implications of L-arginine-nitric oxide pathway impairment.
    Rajapakse NW; Nanayakkara S; Kaye DM
    Pharmacol Ther; 2015 Oct; 154():1-12. PubMed ID: 25989232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT2 inhibitors in the treatment of type 2 cardiorenal syndrome: Focus on renal tubules.
    Wang Y; Mao X; Shi S; Xu X; Lv J; Zhang B; Wu H; Song Q
    Front Nephrol; 2022; 2():1109321. PubMed ID: 37674989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.